AGP Executive Report
Last update: 8 hours agoCancer Immunotherapy Breakthroughs: Taiwan’s Tang Prize 2026 Biopharmaceutical Science honors Steven A. Rosenberg, Michel Sadelain, and Carl H. June for tumor-infiltrating lymphocyte (TIL) and CAR-T therapies, spotlighting how “living drugs” can turn a patient’s immune system into cancer-fighting medicine. Drug Licensing for Kidney Disease: Dimerix signed an exclusive license with Everest Medicines to commercialize DMX-200 (all indications, including focal segmental glomerulosclerosis) across Greater China, Taiwan, South Korea, and parts of Southeast Asia, with a US$10M upfront payment and up to US$330M in milestones plus 10–15% royalties. Infant Formula Safety Check: Taiwan TFDA said a suspected U.S. infant botulism-linked formula (Nara Organics Whole Milk Infant Formula) has not been imported into Taiwan for at least three years and is not registered locally; consumers were urged to watch for botulism symptoms. Wellness Market Trend in Malaysia: A June 23 Global Wellness Forum in Kuala Lumpur will focus on next-gen nutraceuticals, with Taiwanese R&D teams highlighting “food-like” supplement formats such as Halal-certified FRESH-Jelly. AI in Healthcare Dispatch Raises Questions: A Seattle Fire Department case reports AI used to triage 911 medical calls without caller disclosure, raising concerns about transparency and oversight. Health Tech & Infrastructure: Schneider Electric and Foxconn announced collaboration to scale next-gen AI data centers, aiming to speed deployment of power and cooling systems that underpin healthcare AI growth.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.